A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a ...
Stocktwits on MSN
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call
Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion. ・The company retired its senior loan ...
Stocktwits on MSN
Eli Lilly Cuts Prices For Weight Loss Drug Zepbound To $299 A Month As It Takes On Novo Nordisk’s Wegovy
Eli Lilly & Co. (LLY) on Monday announced a price cut for its blockbuster weight-loss drug, Zepbound, as it looks to match a ...
Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906).
In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.
By Bhanvi Satija and Maggie Fick LONDON (Reuters) -Novo Nordisk shares rose 5% on Wednesday after analysts said negotiated ...
Eli Lilly and Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...
Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment ...
In the early November announcement of its agreement with the government, Lilly pledged to reduce the self-pay price of ...
Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's closely-watched Alzehimer's trials - which failed on Monday to show it ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback